Most Read Articles
Dr Margaret Shi, 3 days ago

A recent cross-sectional study shows that the mental health burden (ie, symptoms of depression, anxiety, insomnia, acute stress) associated with coronavirus disease 2019 (COVID-19) is considerable in China, particularly among individuals with confirmed or suspected COVID-19 and those exposed to patients with COVID-19 at work.

Understanding disease pathology and drug selection to maximise outcomes in schizophrenia treatment

20 Jun 2020
The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 3 days ago

A recent cross-sectional study shows that the mental health burden (ie, symptoms of depression, anxiety, insomnia, acute stress) associated with coronavirus disease 2019 (COVID-19) is considerable in China, particularly among individuals with confirmed or suspected COVID-19 and those exposed to patients with COVID-19 at work.